Q2 revenue grew 44% year-over-year to $335 million, driven by strong oncology, biopharma, and screening performance. FDA approvals, ACS guideline inclusion, and UnitedHealth coverage expanded Shield's reach to 70 million lives. Raised 2026 revenue guidance and accelerated investments in lab capacity.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.